RxDoctor Payments Data

Elizabeth Willis

Nurse Practitioner · Shreveport, LANPI 1083817969

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,799 of the $6,549 with a category attached, or 88.5%. It is spread thinly across 18 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,549in general payments, 2019–2025

Across 246 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Cvrx, Inc.$1K
  • Boehringer Ingelheim$569
  • Novartis$542
  • Merck$436
  • E.r. Squibb & Sons, L.L.C.$402
  • plus $2K from 12 others

What the payments were for

  • Travel & lodging$73611%
  • Food & beverage$5,79989%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,549 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis15$368,212
EntrestoSacubitril/Valsartan417$351,337
JardianceEmpagliflozin224$167,192
FarxigaDapagliflozin Propanediol255$165,950
EliquisApixaban152$94,790
VerquvoVericiguat15$15,460
XareltoRivaroxaban13$12,780
CorlanorIvabradine Hcl14$9,294
Bumetanide374$8,764
DapagliflozinDapagliflozin Propanediol17$7,835
Potassium Chloride382$4,536
Metoprolol Succinate331$3,278
Spironolactone479$2,709
Digoxin132$1,418
Furosemide367$1,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$399$463,002167 claims
NovartisEntresto$542$351,337417 claims
Boehringer IngelheimJardiance$569$167,192224 claims
AstraZenecaFarxiga$1,468$165,950255 claims
MerckVerquvo$436$15,46015 claims
AmgenCorlanor$14$9,29414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →